MG
RXRX icon

Mather Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Mather Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.78K Sell
1,030
-1,250
-55% -$4.16K ﹤0.01% 1664
2026
Q1 		$7K Buy
+2,280
New +$8.81K ﹤0.01% 1526
2025
Q4 		– Sell
-1,030
Closed -$5.03K – 1454
2025
Q3 		$5.03K Buy
+1,030
New +$5.41K ﹤0.01% 1393

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Mather Group's RXRX Position: Q2 2026 in Review

Mather Group reduced its Recursion Pharmaceuticals (RXRX) stake by 55% in Q2 2026, selling an estimated $4.16K and leaving 1,030 shares worth $3.78K. The position accounts for ﹤0.01% of the portfolio, ranked #1664.

Mather Group first reported a position in RXRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $7K in Q1 2026. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Mather Group held 1,030 shares of Recursion Pharmaceuticals worth $3.78K as of Q2 2026.
  • Mather Group sold 1,250 Recursion Pharmaceuticals shares in Q2 2026, an estimated $4.16K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Mather Group's portfolio in Q2 2026, its #1664 holding.
  • Mather Group first reported a position in Recursion Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Mather Group's Recursion Pharmaceuticals position peaked at $7K in Q1 2026.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Mather Group's 13F filing for Q2 2026, filed 27 Jul 2026.